Triveni Bio Launches with $92M Series A Financing

Published on: 

Company aims to develop functional antibodies for the treatment of immunological & inflammatory disorders.

Triveni Bio, a biotech company focused on pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management. According to a company press release, the financing will support the advancement of TRIV-509, its lead antibody program, for the treatment of atopic dermatitis, asthma, and other I&I indications.


"We are grateful for the support of our investors who understand the upfront benefit of leveraging human genetics – especially learnings from rare Mendelian forms of disease – to expose novel drug targets relevant across multiple common diseases with shared traits," said Vishal Patel, PhD, CEO, Triveni Bio. "Triveni Bio is at a key inflection point as we transition into a clinical stage company with a compelling therapeutic pipeline and talented team."

Reference: Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders. PR Newswire. October 26, 2023. Accessed October 26, 2023.